The Supreme Court on Tuesday will hear oral arguments in the controversial case on the Food and Drug Administration’s approval of the abortion pill mifepristone, but relatively few are familiar with how the drug works.

Nearly 63% of all abortions in the United States in 2023 utilized mifepristone, according to the pro-abortion rights group Guttmacher Institute. However, a recent study from the healthcare policy think tank KFF found that nearly two-thirds of people had not heard of the impending Supreme Court decision on whether the FDA provided sufficient evidence of mifepristone safety before permitting the drug to be sold by mail.